Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats.

about

Visceral Inflammation and Immune Activation Stress the Brain.Gut-Brain Neuroendocrine Signaling Under Conditions of Stress-Focus on Food Intake-Regulatory Mediators The Potential Role of the Dipeptidyl Peptidase-4-Like Activity From the Gut Microbiota on the Host Health

P2860

Q47137050-985C0DF3-8EA6-43CB-A646-643F92F992E9 Q58698003-EF4514FE-0878-4E26-A660-5183CBA6866E Q58719667-8362DE11-BF78-44B3-B933-548BF8DC1799

P2860

Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats.

Item

http://www.wikidata.org/entity/Q50178398

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Glucagon-like peptide-1 analog ...... and gut permeability in rats.

@en

Glucagon-like peptide-1 analog ...... and gut permeability in rats.

@nl

type

Item

label

Glucagon-like peptide-1 analog ...... and gut permeability in rats.

@en

Glucagon-like peptide-1 analog ...... and gut permeability in rats.

@nl

prefLabel

Glucagon-like peptide-1 analog ...... and gut permeability in rats.

@en

Glucagon-like peptide-1 analog ...... and gut permeability in rats.

@nl

P1476

Glucagon-like peptide-1 analog ...... n and gut permeability in rats

@en

P2093

Kaoru Takakusaki

http://www.w3.org/2001/XMLSchema#string

Rintaro Nozu

http://www.w3.org/2001/XMLSchema#string

Saori Miyagishi

http://www.w3.org/2001/XMLSchema#string

Shima Kumei

http://www.w3.org/2001/XMLSchema#string

Tsukasa Nozu

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation in irritable bowel syndrome: Myth or new treatment target?

The Physiology of Glucagon-like Peptide 1

Stress and visceral pain: from animal models to clinical therapies

Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes.

Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.

Is irritable bowel syndrome a low-grade inflammatory bowel disease?

Urocortin 2 acts centrally to delay gastric emptying through sympathetic pathways while CRF and urocortin 1 inhibitory actions are vagal dependent in rats.

Immune activation in patients with irritable bowel syndrome.

The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating β-endorphin release from spinal microglia.

Clinical trial: the glucagon-like peptide-1 analogue ROSE-010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo-controlled, double-blind study.

P304

232-239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JGH.13808

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

T Okumura

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28440889

http://www.w3.org/2001/XMLSchema#string

Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats.

about

P2860

P2860

Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698